Treatment of Strongyloides Hyperinfection Syndrome

Immediate Management

The American Gastroenterological Association recommends initiating parenteral ivermectin immediately for Strongyloides hyperinfection syndrome in immunosuppressed patients, as early implementation can be life-saving, and stopping all immunosuppressive therapy if possible 1, 2
The Infectious Diseases Society of America suggests discontinuing all immunosuppressive medications, including corticosteroids, anti-TNF agents, calcineurin inhibitors, and chemotherapy, if clinically feasible 1, 2

The Centers for Disease Control and Prevention recommends suspecting hyperinfection in any immunosuppressed patient with pneumonia from an endemic area, particularly those on high-dose corticosteroids 1, 3
The World Health Organization notes that eosinophilia is present in up to 70% of cases, but severe hyperinfection may paradoxically lack eosinophilia 1, 3

The American College of Physicians advises against initiating or continuing corticosteroid therapy without treating strongyloidiasis first, as this precipitates potentially fatal hyperinfection 4, 5, 6, 7
The European Society of Clinical Microbiology and Infectious Diseases warns against relying on single-dose ivermectin in immunocompromised patients, as this approach has resulted in fatal relapses 4, 5

The American College of Cardiology identifies patients on corticosteroids, especially >20 mg prednisone daily, as high-risk for strongyloidiasis hyperinfection syndrome 1, 4, 5
The Infectious Diseases Society of America notes that patients receiving anti-TNF therapy, calcineurin inhibitors, or chemotherapy are at high risk for strongyloidiasis hyperinfection syndrome 1, 2

Repeated stool examinations using specialized techniques (Baermann concentration method) should be performed to document clearance, though sensitivity remains poor even with multiple specimens, as recommended by the Clinical Infectious Diseases guideline 8
Patients from endemic areas (tropics, subtropics, Southeast Asia, Latin America, sub-Saharan Africa) receiving immunosuppression should be evaluated for strongyloidiasis, according to the Clinical Infectious Diseases guideline 8

Patients on corticosteroids (especially >20 mg prednisone daily), anti-TNF therapy, calcineurin inhibitors, or chemotherapy are at high risk of strongyloidiasis, as indicated by the Clinical Infectious Diseases guideline 8
Any patient from endemic areas receiving immunosuppression should receive empiric ivermectin treatment, given the low sensitivity of diagnostic tests, as recommended by the Clinical Infectious Diseases guideline 8